Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Lazzarin

Showing results (351-360 of 384) with videos related to

Pageof 39
Sort By:
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 7, 2015
Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN studyS Nozza, L Galli, A Antinori, et al.
Antiviral Therapy|August 1, 1996
A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infectionS Vella, A Lazzarin, G Carosi, et al.
The Journal of General Virology|January 22, 2005
Predictive value of anti-cell and anti-human immunodeficiency virus (HIV) humoral responses in HIV-1-exposed seronegative cohorts of European and Asian originL Lopalco, C Barassi, C Paolucci, et al.
Neurology|February 26, 2000
Role of brain biopsy in the management of focal brain lesions in HIV-infected patients. Gruppo Italiano Cooperativo AIDS & TumoriA Antinori, A Ammassari, R Luzzati, et al.
Infection|August 12, 2009
Occult hepatitis B virus infection in a cohort of HIV-positive patients: correlation with hepatitis C virus coinfection, virological and immunological featuresG Morsica, F Ancarani, S Bagaglio, et al.
The Journal of Infectious Diseases|April 25, 2001
Efficacy of low-dose intermittent subcutaneous interleukin (IL)--2 in antiviral drug--experienced human immunodeficiency virus--infected persons with detectable virus load: a controlled study of 3 il-2 regimens with antiviral drug therapyG Tambussi, S Ghezzi, S Nozza, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 24, 2016
Hemophilia and nonprogressing human immunodeficiency virus type 1 infectionE Vicenzi, P Bagnarelli, E Santagostino, et al.
Annali Dell'Istituto Superiore Di Sanita|March 18, 2000
Idiopathic chronic fatigue and chronic fatigue syndrome: a comparison of two case-definitionsC Arpino, M P Carrieri, G Valesini, et al.
HIV Medicine|February 10, 2009
Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136)P Yeni, A Lamarca, D Berger, et al.
Blood|January 1, 1997
Hemophilia and nonprogressing human immunodeficiency virus type 1 infectionE Vicenzi, P Bagnarelli, E Santagostino, et al.
Pageof 39

Showing results (351-360 of 384) with videos related to

Sort By:
Pageof 39
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 7, 2015
Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN studyS Nozza, L Galli, A Antinori, et al.
Antiviral Therapy|August 1, 1996
A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infectionS Vella, A Lazzarin, G Carosi, et al.
The Journal of General Virology|January 22, 2005
Predictive value of anti-cell and anti-human immunodeficiency virus (HIV) humoral responses in HIV-1-exposed seronegative cohorts of European and Asian originL Lopalco, C Barassi, C Paolucci, et al.
Neurology|February 26, 2000
Role of brain biopsy in the management of focal brain lesions in HIV-infected patients. Gruppo Italiano Cooperativo AIDS & TumoriA Antinori, A Ammassari, R Luzzati, et al.
Infection|August 12, 2009
Occult hepatitis B virus infection in a cohort of HIV-positive patients: correlation with hepatitis C virus coinfection, virological and immunological featuresG Morsica, F Ancarani, S Bagaglio, et al.
The Journal of Infectious Diseases|April 25, 2001
Efficacy of low-dose intermittent subcutaneous interleukin (IL)--2 in antiviral drug--experienced human immunodeficiency virus--infected persons with detectable virus load: a controlled study of 3 il-2 regimens with antiviral drug therapyG Tambussi, S Ghezzi, S Nozza, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 24, 2016
Hemophilia and nonprogressing human immunodeficiency virus type 1 infectionE Vicenzi, P Bagnarelli, E Santagostino, et al.
Annali Dell'Istituto Superiore Di Sanita|March 18, 2000
Idiopathic chronic fatigue and chronic fatigue syndrome: a comparison of two case-definitionsC Arpino, M P Carrieri, G Valesini, et al.
HIV Medicine|February 10, 2009
Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136)P Yeni, A Lamarca, D Berger, et al.
Blood|January 1, 1997
Hemophilia and nonprogressing human immunodeficiency virus type 1 infectionE Vicenzi, P Bagnarelli, E Santagostino, et al.
Pageof 39